TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01452763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Study: NCT01748279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: 12mcg of Foradil BID as maintenance COPD treatment in both treatment arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol
Description: 12mcg of Foradil BID as maintenance COPD treatment in both treatment arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablet
Description: One lactose tablet taken once a day as add-on treatment to Formoterol therapy
Study: NCT00964743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoCyt
Description: Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients received oral sorafenib at 400 mg twice a day
Study: NCT01784770

Intervention type: DRUG
Intervention: Azithromycin IV
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study: NCT03068442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imaging with flutemetamol F 18 PET/CT
Description: All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
Study: NCT00781911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot octreotide
Description: Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot octreotide
Description: Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
Study: NCT04342754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: The device will be ON

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The device will be OFF
Study: NCT03212053

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)
Description: Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
Study: NCT01530204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy for knee OA
Description: 8-12 sessions of knee-focused physical therapy and a home-based conditioning program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain CBT-P
Description: 8-12 session pain-focused Cognitive Behavioral Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
Study: NCT01982929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block (Bupivacaine 0.25% with epinephrine)
Description: Ultrasound guided TAP blocks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block control
Description: A blunt needleless syringe was firmly pressed on either side of the abdomen.
Study: NCT02547350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmorubicin or pirarubicin
Description: pharmorubicin 50mg pirarubicin 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmorubicin or pirarubicin
Description: pharmorubicin 50mg pirarubicin 30mg
Study: NCT02373059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Issue Cards Decision Aids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Pharmaceutical Care
Study: NCT04378530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Anchoring Strategy
Description: The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Anchoring Strategy Control
Description: The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Anchoring Strategy
Description: The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
Study: NCT00047060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A matched peripheral donor stem cells
Description: A matched peripheral donor stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath
Study: NCT02247895

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
Study: NCT02238873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT01586351

Intervention type: DEVICE
Intervention: Patch Augmentation and ACP injection
Description: Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
Study: NCT02189213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline will be administered to treat anxiety disorders in children and adolescents.
Study: NCT04457050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 milligram
Description: single daily dose of 400 milligrams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 milligram
Description: single daily dose of 60 milligrams for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 400 milligram
Description: weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab
Description: single daily dose for 12 weeks
Study: NCT04045288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation
Description: Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation
Description: Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
Study: NCT02672670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention group---coping-oriented supportive programme

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Comparison group---a didactic talk (usual care)
Study: NCT02134483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Parathyroid allo-transplantation
Description: parathyroid allotransplantation with a new tecnique without immunosuppression
Study: NCT02989831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating insoles 'on'
Description: Duration: 30-60 seconds
Study: NCT01035554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Paced Programmed Instruction (SPPI)
Description: If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Paced Programmed Instruction (SPPI)
Description: If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitor
Description: The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitor
Description: The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed Materials
Description: National Institutes of Health Printed Materials on hypertension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Materials
Description: National Institutes of Health Printed Materials on hypertension
Study: NCT03621514

Intervention type: PROCEDURE
Group type: OTHER
Intervention: painless indwelling catheter
Description: Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: indwelling catheter
Description: The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
Study: NCT03359512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: qCON monitor
Description: supervision by qCON monitor of the depth of anesthesia
Study: NCT03658382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: Patients will receive the results of their genetic testing via a virtual visit.
Study: NCT01505790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRASUGREL
Description: 60 mg the first day then 10 mg per day during one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least.
Study: NCT02524574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomography Positron Emission
Study: NCT00917150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetomilast (OPC-6535)
Description: oral administration of 12.5mg OPC-6535, once daily for 24months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetomilast (OPC-6535)
Description: oral administration of 25mg OPC-6535, once daily for 24months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetomilast (OPC-6535)
Description: oral administration of 50 mg OPC-6535, once daily for 24months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of placebo, once daily for 24months
Study: NCT01587911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey
Description: Preload containing complete whey protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey-CMP
Description: Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Preload control matched for energy to the other 5 preloads.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMP
Description: Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MPI
Description: Preload containing whole milk protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPI
Description: Preload containing sodium caseinate.
Study: NCT03184961

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung recruitment maneuver
Description: Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
Study: NCT05520697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Nutritional treatment with caloric restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Nutritional treatment with caloric restriction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental exercise.
Description: Mental exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental exercise.
Description: Mental exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training.
Description: Exercise.
Study: NCT03234244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene 20 mg
Description: To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20mg and Cholecalciferol
Description: For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
Study: NCT02302976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02023645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: active supplement
Description: tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet
Study: NCT02613936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training involves solving executive function tasks on a computer.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Cognitive training involves solving executive function tasks on a computer.
Study: NCT01063374

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic diet instruction

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high cereal fibre diet instruction
Study: NCT00676390

Intervention type: OTHER
Group type: OTHER
Intervention: doubly labelled water and questionnaire
Description: 0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
Study: NCT02703311

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioband
Description: Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
Study: NCT00715585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: int arm 1
Description: VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: int arm 3
Description: patients receive 3 individualized visits with an rd-cde for education focused on carb counting